{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:40:23Z","timestamp":1772757623826,"version":"3.50.1"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2000,3,1]],"date-time":"2000-03-01T00:00:00Z","timestamp":951868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2000,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Paraneoplastic pemphigus (PNP) is a rare autoimmune blistering disease with circulating antibodies that bind the cell surface of the epidermis and other non-stratifying epithelia, and immunoprecipitate a complex of four or five proteins (250 kDa, 230 kDa, 210 kDa, 190 kDa and occasionally 170 kDa). 1, 2 Combinations of immunosuppressive agents are usually required to obtain even partial control of the skin lesions. 3 Mucous membrane lesions are refractory to treatment. We describe a patient with PNP whose skin and oral lesions are quiescent following treatment with oral mycophenolate mofetil.<\/jats:p>","DOI":"10.1046\/j.1365-2133.2000.03365.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T05:24:51Z","timestamp":1047360291000},"page":"506-508","source":"Crossref","is-referenced-by-count":64,"title":["Use of mycophenolate mofetil in the treatment of paraneoplastic pemphigus"],"prefix":"10.1093","volume":"142","author":[{"given":"J.V.","family":"Williams","sequence":"first","affiliation":[{"name":"Section of Dermatology, The Penn State University College of Medicine, Penn State Geisinger Health System, The Milton S. Hershey Medical Center, Hershey, Pennsylvania, PA, U.S.A."},{"name":"Paediatric and Adolescent Dermatology, Children\u2019s Hospital and Health Center, San Diego, CA, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.G.","family":"Marks JR.","sequence":"additional","affiliation":[{"name":"Section of Dermatology, The Penn State University College of Medicine, Penn State Geisinger Health System, The Milton S. Hershey Medical Center, Hershey, Pennsylvania, PA, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.M.","family":"Billingsley","sequence":"additional","affiliation":[{"name":"Section of Dermatology, The Penn State University College of Medicine, Penn State Geisinger Health System, The Milton S. Hershey Medical Center, Hershey, Pennsylvania, PA, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2000,3,1]]},"reference":[{"key":"2023012714364254500_b1","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1056\/NEJM199012203232503","article-title":"Paraneoplastic pemphigus: an autoimmune mucocutaneous disease associated with neoplasia","volume":"323","author":"Anhalt","year":"1990","journal-title":"N Engl J Med"},{"key":"2023012714364254500_b2","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/1523-1747.ep12607012","article-title":"Characterization of paraneoplastic pemphigus antigens by immunoblot analysis.","volume":"104","author":"Hashimoto","year":"1995","journal-title":"J Invest Dermatol"},{"key":"2023012714364254500_b3","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1001\/archderm.1993.01680280071014","article-title":"Paraneoplastic pemphigus is a distinct neoplasia-induced autoimmune disease.","volume":"129","author":"Camisa","year":"1993","journal-title":"Arch Dermatol"},{"key":"2023012714364254500_b4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1600-065X.1993.tb00652.x","article-title":"Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil.","volume":"136","author":"Allison","year":"1993","journal-title":"Immunol Rev"},{"key":"2023012714364254500_b5","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/00007691-199512000-00025","article-title":"Mycophenolate mofetil: a report of the consensus panel","volume":"17","author":"Shaw","year":"1995","journal-title":"Ther Drug Monit"},{"key":"2023012714364254500_b6","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(96)10310-X","article-title":"Mycophenolate mofetil.","volume":"348","author":"Lipsky","year":"1996","journal-title":"Lancet"},{"key":"2023012714364254500_b7","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S0190-9622(87)70285-0","article-title":"Mycophenolic acid for psoriasis: a review of pharmacology, long-term efficacy, and safety.","volume":"17","author":"Epinette","year":"1987","journal-title":"J Am Acad Dermatol"},{"key":"2023012714364254500_b8","first-page":"S117","article-title":"Therapy of rheumatoid arthritis with mycophenolate mofetil.","volume":"11","author":"Goldblum","year":"1993","journal-title":"Clin Exp Rheumatol"},{"key":"2023012714364254500_b9","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0190-9622(18)30747-3","article-title":"Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses","volume":"37","author":"Kitchin","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"2023012714364254500_b10","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S0140-6736(05)63084-X","article-title":"Treatment of pemphigus vulgaris with mycophenolate mofetil. (Letter.)","volume":"350","author":"Enk","year":"1997","journal-title":"Lancet"},{"key":"2023012714364254500_b11","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(97)80092-X","article-title":"Bullous pemphigoid treated with mycophenolate mofetil. (Letter.)","volume":"349","author":"Bohm","year":"1997","journal-title":"Lancet"},{"key":"2023012714364254500_b12","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0190-9622(98)70334-2","article-title":"Successful therapy for bullous pemphigoid with mycophenolate mofetil.","volume":"39","author":"Nousari","year":"1998","journal-title":"J Am Acad Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2133.2000.03365.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/142\/3\/506\/48940229\/bjd0506.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/142\/3\/506\/48940229\/bjd0506.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T12:28:26Z","timestamp":1676377706000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/142\/3\/506\/6689631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,3,1]]},"references-count":12,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2000,3,1]]},"published-print":{"date-parts":[[2000,3,1]]}},"URL":"https:\/\/doi.org\/10.1046\/j.1365-2133.2000.03365.x","relation":{},"ISSN":["1365-2133","0007-0963"],"issn-type":[{"value":"1365-2133","type":"electronic"},{"value":"0007-0963","type":"print"}],"subject":[],"published-other":{"date-parts":[[2000,3,1]]},"published":{"date-parts":[[2000,3,1]]}}}